Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q2 2018 call → NOWe need answer YES/NO. Need analyze transcript. Question: Does management describe mismatch of scale between company and demand it is already serving? Need both: already inside with real business, and management draws size contrast treating as point. Let's examine transcript. Management discusses two initiatives: Chongqing JV and digital power. Also core business. Need see if they describe current participation in something enormous relative to company, with modest share making several times bigger. Key passages: Mike Chang: "As the demand for our new products has increased in the last year or so, we have experienced and expect to continue to experience supply and manufacturing constraints. These capacity constraints have caused us to forgo potential revenue, on an annualized basis, in the order of tens of millions of dollars. We believe this joint venture will provide us with the needed manufacturing capacity to meet the demand for our products and to support our longer-term revenue growth." This is about capacity constraints, not mismatch of scale with demand? It says forgoing tens of millions revenue due to supply constraints. That is not necessarily enormous relative to company? Company revenue ~$100M/quarter, $400M/year. Tens of millions is 10-20%, not several times bigger. Not enough. Digital power: "With digital power capability, we have opportunities to expand into broad markets where the semiconductor content is rapidly increasing. These include the computer server market, which has an additional $400 million BOM content for us to tap." This is a market opportunity, but is company already inside it? They acquired digital power team, building team, developing products for Intel VR13.HC platform, revenue expected 2-3 years down road. So not already earning from it. It's prospective. No. Other segments: Computing, Consumer, etc. They report growth, market share gains. No explicit size contrast with enormous flow. IGBT crossed $10M annual revenue, broad market. But not "already inside enormous flow" with modest share? They mention IGBT product line crossed $10M annual revenue, gaining momentum. Not enough.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.